AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies

https://finance.yahoo.com/news/axim-biotechnologies-files-emergency-authorization-130000236.html

AXIM® Biotech CEO John W. #Huemoeller II commented

“Our ultimate goal is to get Tru-19 approved and manufactured as a point-of-care test as quickly possible.

We are confident that once care providers see how easy to use Tru-19 is, it will become the go-to choice for assessing levels of immunity and protection against re-infection.

All roads point to neutralizing antibodies as a key measurement in defeating COVID-19.”

#TRU19 #SARSCoV2